APPLICATION
BLA761320
TYPE
BLA
ORIGINAL APPROVAL
2026-07-24
LATEST ACTION
2026-07-24
ROUTE
SINGLE-DOSE
DOSAGE FORM
VIAL
MARKETING STATUS
Prescription
Products
LYTENAVAPrescription
BEVACIZUMAB-VIKG 1.25MG (0.05ML of 25MG/ML · VIAL · SINGLE-DOSE
Approval history
2026-07-24Type 1 - New Molecular Entity and Type 4 - New Combination · Original · standard — Label ↗AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.